Literature DB >> 16528452

Hyperphosphatemic familial tumoral calcinosis caused by a mutation in GALNT3 in a European kindred.

Polina Specktor1,2, John G Cooper3, Margarita Indelman1, Eli Sprecher4,5,6.   

Abstract

Hyperphosphatemic familial tumoral calcinosis (HFTC) is an autosomal recessive metabolic disorder characterized by extensive phenotypic and genetic heterogeneity. HFTC was shown recently to result from mutations in two genes: GALNT3, coding for a glycosyltransferase responsible for initiating O-glycosylation, and FGF23, coding for a potent phosphaturic protein. All GALNT3 mutations reported so far have been identified in patients of either Middle Eastern or African-American extraction, corroborating numerous historical reports of the disorder in Africa and in the Middle East. In the present study, we describe a patient of Northern European origin displaying typical features of HFTC. Mutation analysis revealed that this patient carries a homozygous novel nonsense mutation in GALNT3 predicted to result in the synthesis of a significantly truncated protein. The present results expand the spectrum of known mutations in GALNT3 and demonstrate the existence of HFTC-causing mutations in this gene outside the Middle Eastern and African-American populations.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16528452     DOI: 10.1007/s10038-006-0377-6

Source DB:  PubMed          Journal:  J Hum Genet        ISSN: 1434-5161            Impact factor:   3.172


  23 in total

1.  Identification of a recurrent mutation in GALNT3 demonstrates that hyperostosis-hyperphosphatemia syndrome and familial tumoral calcinosis are allelic disorders.

Authors:  Yaacov Frishberg; Orit Topaz; Reuven Bergman; Doron Behar; Drora Fisher; Derek Gordon; Gabriele Richard; Eli Sprecher
Journal:  J Mol Med (Berl)       Date:  2004-12-15       Impact factor: 4.599

2.  Vitamin D receptor-independent FGF23 actions in regulating phosphate and vitamin D metabolism.

Authors:  Takashi Shimada; Yuji Yamazaki; Motoo Takahashi; Hisashi Hasegawa; Itaru Urakawa; Takeshi Oshima; Kaori Ono; Makoto Kakitani; Kazuma Tomizuka; Toshiro Fujita; Seiji Fukumoto; Takeyoshi Yamashita
Journal:  Am J Physiol Renal Physiol       Date:  2005-07-05

3.  Gains of glycosylation comprise an unexpectedly large group of pathogenic mutations.

Authors:  Guillaume Vogt; Ariane Chapgier; Kun Yang; Nadia Chuzhanova; Jacqueline Feinberg; Claire Fieschi; Stéphanie Boisson-Dupuis; Alexandre Alcais; Orchidée Filipe-Santos; Jacinta Bustamante; Ludovic de Beaucoudrey; Ibrahim Al-Mohsen; Sami Al-Hajjar; Abdulaziz Al-Ghonaium; Parisa Adimi; Mehdi Mirsaeidi; Soheila Khalilzadeh; Sergio Rosenzweig; Oscar de la Calle Martin; Thomas R Bauer; Jennifer M Puck; Hans D Ochs; Dieter Furthner; Carolin Engelhorn; Bernd Belohradsky; Davood Mansouri; Steven M Holland; Robert D Schreiber; Laurent Abel; David N Cooper; Claire Soudais; Jean-Laurent Casanova
Journal:  Nat Genet       Date:  2005-05-29       Impact factor: 38.330

4.  Role of the vitamin D receptor in FGF23 action on phosphate metabolism.

Authors:  Yoshio Inoue; Hiroko Segawa; Ichiro Kaneko; Setsuko Yamanaka; Kenichiro Kusano; Eri Kawakami; Junya Furutani; Mikiko Ito; Masashi Kuwahata; Hitoshi Saito; Naoshi Fukushima; Shigeaki Kato; Hiro-Omi Kanayama; Ken-ichi Miyamoto
Journal:  Biochem J       Date:  2005-08-15       Impact factor: 3.857

5.  A novel mutation in fibroblast growth factor 23 gene as a cause of tumoral calcinosis.

Authors:  Kaori Araya; Seiji Fukumoto; Rebecca Backenroth; Yasuhiro Takeuchi; Kounosuke Nakayama; Nobuaki Ito; Nozomi Yoshii; Yuji Yamazaki; Takeyoshi Yamashita; Justin Silver; Takashi Igarashi; Toshiro Fujita
Journal:  J Clin Endocrinol Metab       Date:  2005-07-19       Impact factor: 5.958

Review 6.  Post-translational modification of Fibroblast Growth Factor 23.

Authors:  Seiji Fukumoto
Journal:  Ther Apher Dial       Date:  2005-08       Impact factor: 1.762

7.  Inhibition of intestinal sodium-dependent inorganic phosphate transport by fibroblast growth factor 23.

Authors:  Ken-ichi Miyamoto; Mikiko Ito; Masashi Kuwahata; Shigeaki Kato; Hiroko Segawa
Journal:  Ther Apher Dial       Date:  2005-08       Impact factor: 1.762

8.  Mutations in GALNT3, encoding a protein involved in O-linked glycosylation, cause familial tumoral calcinosis.

Authors:  Orit Topaz; Daniel L Shurman; Reuven Bergman; Margarita Indelman; Paulina Ratajczak; Mordechai Mizrachi; Ziad Khamaysi; Doron Behar; Dan Petronius; Vered Friedman; Israel Zelikovic; Sharon Raimer; Arieh Metzker; Gabriele Richard; Eli Sprecher
Journal:  Nat Genet       Date:  2004-05-09       Impact factor: 38.330

9.  Tumoral calcinosis--an unrecognized disease.

Authors:  S McClatchie; A D Bremner
Journal:  Br Med J       Date:  1969-01-18

Review 10.  All in the family: the UDP-GalNAc:polypeptide N-acetylgalactosaminyltransferases.

Authors:  Kelly G Ten Hagen; Timothy A Fritz; Lawrence A Tabak
Journal:  Glycobiology       Date:  2002-11-01       Impact factor: 4.313

View more
  25 in total

Review 1.  Clinical manifestations and pathogenesis of hydroxyapatite crystal deposition in juvenile dermatomyositis.

Authors:  Lauren M Pachman; Adele L Boskey
Journal:  Curr Rheumatol Rep       Date:  2006-06       Impact factor: 4.592

2.  Disorders of human dentin.

Authors:  P Suzanne Hart; Thomas C Hart
Journal:  Cells Tissues Organs       Date:  2007       Impact factor: 2.481

Review 3.  Disorders of phosphate homeostasis and tissue mineralisation.

Authors:  Clemens Bergwitz; Harald Jüppner
Journal:  Endocr Dev       Date:  2009-06-03

Review 4.  Novel functions of circulating Klotho.

Authors:  Julia M Hum; Linda O'Bryan; Rosamund C Smith; Kenneth E White
Journal:  Bone       Date:  2016-11-23       Impact factor: 4.398

5.  Novel mutations in GALNT3 causing hyperphosphatemic familial tumoral calcinosis.

Authors:  Alan Yancovitch; Dov Hershkovitz; Margareta Indelman; Peter Galloway; Margo Whiteford; Eli Sprecher; Esra Kılıç
Journal:  J Bone Miner Metab       Date:  2011-02-25       Impact factor: 2.626

6.  Clinical variability of familial tumoral calcinosis caused by novel GALNT3 mutations.

Authors:  Shoji Ichikawa; Geneviève Baujat; Aksel Seyahi; Anastasia G Garoufali; Erik A Imel; Leah R Padgett; Anthony M Austin; Andrea H Sorenson; Zagorka Pejin; Vicken Topouchian; Pierre Quartier; Valerie Cormier-Daire; Michele Dechaux; Fotini Ch Malandrinou; Panagiotis N Singhellakis; Martine Le Merrer; Michael J Econs
Journal:  Am J Med Genet A       Date:  2010-04       Impact factor: 2.802

7.  A homozygous missense mutation in human KLOTHO causes severe tumoral calcinosis.

Authors:  Shoji Ichikawa; Erik A Imel; Mary L Kreiter; Xijie Yu; Donald S Mackenzie; Andrea H Sorenson; Regina Goetz; Moosa Mohammadi; Kenneth E White; Michael J Econs
Journal:  J Clin Invest       Date:  2007-09       Impact factor: 14.808

8.  A case of familial tumoral calcinosis/hyperostosis-hyperphosphatemia syndrome due to a compound heterozygous mutation in GALNT3 demonstrating new phenotypic features.

Authors:  C E Dumitrescu; M H Kelly; A Khosravi; T C Hart; J Brahim; K E White; E G Farrow; M H Nathan; M D Murphey; M T Collins
Journal:  Osteoporos Int       Date:  2008-11-04       Impact factor: 4.507

9.  Ablation of the Galnt3 gene leads to low-circulating intact fibroblast growth factor 23 (Fgf23) concentrations and hyperphosphatemia despite increased Fgf23 expression.

Authors:  Shoji Ichikawa; Andrea H Sorenson; Anthony M Austin; Donald S Mackenzie; Timothy A Fritz; Akira Moh; Siu L Hui; Michael J Econs
Journal:  Endocrinology       Date:  2009-02-12       Impact factor: 4.736

10.  Newly discovered mutations in the GALNT3 gene causing autosomal recessive hyperostosis-hyperphosphatemia syndrome.

Authors:  Faysal Gok; Ilana Chefetz; Margarita Indelman; Murat Kocaoglu; Eli Sprecher
Journal:  Acta Orthop       Date:  2009-02       Impact factor: 3.717

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.